Sarepta Therapeutics · 15 hours ago
Research Scientist I
New York, NY
Full-time
Hybrid
Entry, Mid Level
$103K/yr - $129K/yr
1+ years expSarepta Therapeutics is at the forefront of genetic medicine, focusing on Duchenne muscular dystrophy and other diseases. The Research Scientist I will support Genomics and Data Science projects, collaborating on software solutions for R&D programs and developing applications for managing genetic data.
BiotechnologyGeneticsHealth CareTherapeutics
No H1B
Responsibilities
Collaborate on and maintain software solutions to support R&D programs; platforms, reporting, and analytics
Develop and maintain apps and dashboards for managing and annotating genetic data, joining them with other datasets, aggregating them for reporting
Support and contribute to siRNA program analysis pipelines, their validation, and the reporting of their results
Qualification
Required
MS / Ph.D. in a STEM discipline with prior software engineering experience: MS with 4+ years of hands-on experience in the biotech/pharmaceutical industry or Ph.D. with 1+ years of professional experience
Applied knowledge of software design patterns, data modeling, and software architecture
Prior experience in bioinformatics and utilizing scientific discipline-specific datatypes, e.g. VCF, CRAM/BAM, or similar experience in another scientific field
Strong Proficiency in Python and/or R and developing in a (containerized) Linux environment
Proficiency in relational database interaction and/or data warehousing
Basic Experience with AWS services (EC2, S3, Batch etc.)
Undergraduate level of genetics understanding
Excellent written and verbal communication skills
Preferred
Experience with workflow definition frameworks e.g. Dagster, Airflow and/or Nextflow preferred
Experience with web-based data visualization frameworks including R/Shiny and Python/Streamlit a plus
Benefits
Physical and Emotional Wellness
Financial Wellness
Support for Caregivers
Company
Sarepta Therapeutics
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$2.88BKey Investors
Michael Andrew ChambersPharmakon AdvisorsMidCap Financial
2025-12-11Post Ipo Debt· $291.4M
2025-08-21Post Ipo Equity
2025-08-21Post Ipo Debt· $602M
Leadership Team
Ian Estepan
Executive Vice President, Chief Financial Officer
K
Kathy Behrens Wilsey
Director
Recent News
2026-01-24
Genetic Engineering News
2026-01-23
Company data provided by crunchbase